Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 51Leukemia 28Burkitt Lymphoma 6Recurrence 5Lymphoma 5Leukemia, Biphenotypic, Acute 3Lymphoma, T-Cell 2Lymphoma, Extranodal NK-T-Cell 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasms 1Neoplasm, Residual 1Mucositis 1Lymphoproliferative Disorders 1Leukemia, T-Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphoid 1Immunoproliferative Disorders 1Fallopian Tube Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Down Syndrome 1Dendritic Cell Sarcoma, Interdigitating 1Blast Crisis 1

Interventions

dacetuzumab 5blinatumomab 4Bortezomib 4Lenalidomide 3Dexamethasone 3Rituximab 2tetulomab tetraxetan lu-177 1ponatinib 1pembrolizumab 1pegaspargase 1isatuximab 1ibrutinib 1ficlatuzumab 1durvalumab 1asparaginase erwinia chrysanthemi recombinant 1acalabrutinib 1Vorinostat 1Methotrexate 1Lutetium 1KW-2478 1Ifosfamide 1Hsp90 inhibitor KU757 1Gemcitabine 1Erlotinib Hydrochloride 1Daunorubicin 1Cyclophosphamide 1Calcium Dobesilate 1Brentuximab Vedotin 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Immunoproliferative Disorders × pegaspargase × Clear all
NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 3 Completed
111 enrolled 23 charts 1 FDA
LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡